Taiho Pharmaceutical Company Limited

Banyu Pharmaceutical Co. Ltd

Msd K.k.

Merck Sharp + Dohme Corp.

Japan Science and Technology Corporation

Japan Science and Technology Agency

Hiroshi Hirai

Takeshi Sagara

Yasuhiro Goto

Toshihiro Sakamoto

Kenji Niiyama

Keiji Takahashi

Hidetomo Furuyama

Makoto Bamba

Fuyuki Yamamoto

Satoshi Sunami

Takashi Yoshizumi

Sachie Otsuki

Toshihide Nishibata

Jun Shibata

Nobuhiko Kawanishi

Susumu Komiyama

Mark E Layton

Yoshikazu Iwasawa

Tadashi Shimamura

Masaaki Hirose

Takashi Mita

Hiroshi Sootome

Sachie Arai

Tetsuya Sugimoto

Hideki Kurihara

Hidehito Kotani

Mikako Kawamura

Takashi Hashihayata

Kouta Masutani

Hiroaki Ochiiwa

Kaori Kamijyo

Antonov Vladimir

Astafiev Oleg

Takeshi Kutsuwa

Antonov Vladmir

Takeshi Sanyo Haitsu No17 Kutsuwa

Provided is an effective method for using an orally administrable compound having an excellent Aurora A selective inhibitory effect, and a microtubule-targeting drug in combination. The present invention provides a method for treatment of malignant tumor by a combination of 1-(2,3-dichlorobenzoyl)-4-[5-fluoro-6-(5-methyl-1H-pyrazol-3-ylamino)pyridin-2-yl]methyl-4-piperidinecarboxylic acid (compound I) or a salt thereof and a microtubule-targeting drug, wherein the following administration schedule thereof is performed: one cycle involves 7 days; the microtubule-targeting drug is administered once; and the compound I or the salt thereof is administered for 3 consecutive days with cessation of the drug for remaining 4 days.

Antitumor agent and method for tumor therapy

The problems to be solved by the present invention are to provide a novel FGFR inhibitor that is potent and highly selective, and to provide an antitumor agent with which side effects such as an elevated blood phosphorus concentration are alleviated while maintaining the antitumor effect of the FGFR inhibitor. The present invention provides an antitumor agent comprising a 3,5-di-substituted benzene alkynyl compound represented by general formula (I) or salt thereof, which is used by administering the 3,5-di-substituted benzene alkynyl compound or salt thereof according to an administration schedule of two or more times/week at an administration interval of at least one day between doses.

Antitumor drug for intermittent administration of FGFR inhibitor

A method for treating a tumor by combining a piperidine compound of formula (I) or salt thereof and a microtubule-targeting drug, in which the microtubule-targeting drug is administered once per 7 days or more one cycle, and the piperidine compound is administered once or more per day for 4 days or more: 

Method for enhancing anti-tumor effect of a microtubule-targeting drug, and a method for treatment of tumor

The invention relates to compounds of a general formula (I): wherein Aris an optionally-substituted aryl or heteroaromatic group; Ris an optionally-substituted lower alkyl, lower alkenyl, lower alkynyl or cyclo-lower alkyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; Ris a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; Ris a hydrogen atom or a lower alkyl group; Ris a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a group of &#x2014;N(R)R; T and U are a nitrogen atom or a methine group, etc. The compounds of the invention have excellent Weel kinase-inhibitory effect and are therefore useful in the field of medicines, especially treatment of various cancers.

Dihydropyrazolopyrimidinone derivatives

The invention relates to combination anticancer therapy with certain Akt inhibitor and other anticancer agents such as anticancer antimetabolites, anticancer antibiotics, plant-derived anticancer agents, anticancer platinum-coordinated complex compounds, anticancer camptothecin derivatives and anticancer tyrosine kinase inhibitors.

Combination cancer therapy with an AKT inhibitor and other anticancer agents

Substituted pyrazolo[3,4-d]pyrimidinone derivatives

The present invention relates to a compound represented by Formula [I]: wherein

Selective inhibitors against Cdk4 and Cdk6 having aminothiazole skeleton

A quinoxalinone derivative of the formula (I): or a pharmaceutically acceptable salt or ester thereof, wherein; is, for example, the formula: 

Quinoxalinone derivatives

An MR/FIR light detector is disclosed herein that has extraordinarily high degree of sensitivity and a high speed of response. The detector includes an MR/FIR light introducing section ( ) for guiding an incident MR/FIR light ( ), a semiconductor substrate ( ) formed with a single-electron transistor ( ) for controlling electric current passing through a semiconductor quantum dot ( ) formed therein, and a BOTAI antenna ( ) for concentrating the MW/FIR light ( ) into a small special zone of sub-micron size occupied by the semiconductor quantum dot ( ) in the single-electron transistor ( ). The quantum dot ( ) forming a two-dimensional electron system absorbs the electromagnetic wave concentrated efficiently, and retains an excitation state created therein for 10 nanoseconds or more, thus permitting electrons of as many as one millions in number or more to be transferred with respect to a single photon absorbed.

Millimeter wave and far-infrared detector

Growing community of inventors

Tsukuba, Japan

Hiroshi Hirai